ライフサイエンスコーパス: tissue factor pathway inhibitor

1 n sepsis-induced ALI were confirmed by using tissue factor pathway inhibitor.

2 tor Xa, unaffected by subsequent addition of tissue factor pathway inhibitor.

3 n hemophilia, possibly through inhibition of tissue factor pathway inhibitor.

4 urally deleted (Kunitz 1-domainless) form of tissue factor pathway inhibitor.

5 possible disruption of FXa inhibition by the tissue factor pathway inhibitor.

6 d abrogate the anticoagulant function of the tissue factor pathway inhibitor.

7 oduction of tissue plasminogen activator and tissue factor pathway inhibitor.

8 tant to inactivation by antithrombin III and tissue factor pathway inhibitor.

9 nction of the natural anticoagulant protein, tissue factor pathway inhibitor.

10 in-2, and the first two inhibitor domains of tissue factor pathway inhibitor.

11 t (6L15), amyloid beta-protein precursor, or tissue factor pathway inhibitor.

12 ect either protein expression or activity of tissue factor pathway inhibitors.

13 ion of the murine tissue factor (TF) gene or tissue factor pathway inhibitor 1 (TFPI) gene results in

14 Tissue factor pathway inhibitor-1 (TFPI) contains three

15 th factor activator inhibitor type 2 (HAI2), tissue factor pathway inhibitor-1 (TFPI1), and tissue fa

16 One of the genes identified was tissue factor pathway inhibitor 2 (TFPI-2), which encode

17 ased strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential t

18 beta hydroxysteroid dehydrogenase type 2 and tissue factor pathway inhibitor 2.

19 In the presence of plasma levels of the tissue factor pathway inhibitor (2.5 nM recombinant TFPI

20 rt here that the serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-2) can function

21 Tissue factor pathway inhibitor-2 (TFPI-2) inhibits fact

22 Tissue factor pathway inhibitor-2 (TFPI-2) is a homologu

23 Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-t

24 Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-t

25 Human tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-a

26 We have shown previously that the tissue factor pathway inhibitor-2 (TFPI-2), a broad rang

27 Tissue factor pathway inhibitor-2 (TFPI-2), a serine pro

28 ntial DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor

29 ssue factor pathway inhibitor-1 (TFPI1), and tissue factor pathway inhibitor-2 (TFPI2), as well as E-

30 Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 inhibits trypsin, plas

31 nhances the inhibition of factor Xa (FXa) by tissue factor pathway inhibitor-alpha (TFPI-alpha) in th

32 indirect mechanism by forming a complex with tissue factor pathway inhibitor-alpha (TFPIalpha), resul

33 d binds tightly to the coagulation regulator tissue factor pathway inhibitor-alpha (TFPIalpha).

34 Recombinant tissue factor pathway inhibitor, an analogue of the phys

35 fXa for binding to the non-serpin inhibitors tissue factor pathway inhibitor and recombinant tick ant

36 anticoagulant fusion proteins based on human tissue factor pathway inhibitor and the leech anticoagul

37 more sensitive to inhibition by cell surface tissue factor pathway inhibitor and the phospholipid bin

38 e 6- to 86-fold more active than recombinant tissue factor pathway inhibitor and tick anticoagulant p

39 in, high activated protein C, protein S, and tissue factor pathway inhibitor) and hyperfibrinolysis (

40 ith Spectrozyme Xa(TM), antithrombin III and tissue factor pathway inhibitor, and prothrombin than it

41 rs X, IX, II, V, and VIII and the inhibitors tissue factor pathway inhibitor, antithrombin-III, and p

42 coagulation (e.g., antithrombin, protein C, tissue factor pathway inhibitor) are not affected.

43 agulation inhibitors activated protein C and tissue factor pathway inhibitor but also is also a physi

44 increased rate in binding to the two-domain tissue factor pathway inhibitor; Ca(2+) (+/-Na(+)) has n

45 h (p = 0.002) and correlated inversely with tissue factor pathway inhibitor concentration (r = -0.61

46 inhibitor (>10-fold), followed by the second tissue factor pathway inhibitor domain (1.7-fold) and th

47 tely abrogates the anticoagulant function of tissue factor pathway inhibitor, enhances fibrin clot st

48 allenged with CpG DNA, and tissue factor and tissue factor pathway inhibitor expression and activity

49 coagulants, antithrombin III and recombinant tissue factor pathway inhibitor, failed to do so, implyi

50 , phospholipid transfer protein, matrilin-3, tissue factor pathway inhibitor, fibrinogen-like 1, and

51 tion, resulting from loss of FVIIa-dependent tissue factor pathway inhibitor function and the absence

52 Only the tissue factor pathway inhibitor gene demonstrated global

53 lood cells, and an endogenous DPP4 inhibitor tissue factor pathway inhibitor has been discovered, inc

54 c for an "anticoagulant" gene, such as human tissue factor pathway inhibitor, hirudin, or CD39, or la

55 Tissue factor pathway inhibitor, however, remains a plau

56 urring soluble anticoagulant proteins, human tissue factor pathway inhibitor (hTFPI) and the leech pr

57 oagulation inhibitor (LACI-D1, also known as tissue-factor pathway inhibitor-I) displayed on bacterio

58 e factor, a key initiator of coagulation and tissue factor pathway inhibitor in human coronary artery

59 glish language relating to tissue factor and tissue factor pathway inhibitor in intravascular coagula

60 ently completed phase 3 trial of recombinant tissue factor pathway inhibitor in severe sepsis failed

61 Tissue factor pathway inhibitor is a potent inhibitor of

62 25%, inhibition by antithrombin III and the tissue factor pathway inhibitor is approximately 20%, an

63 -45)-protein C were effectively inhibited by tissue factor pathway inhibitor (K1 < 200 nM) and, excep

64 clot formation, decreasing upon induction of tissue factor pathway inhibitor or treatment with hirudi

65 tial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein C, plasminogen

66 Tissue factor pathway inhibitor reduced neointimal forma

67 ssue factor (TF) inhibition with recombinant tissue factor pathway inhibitor (rTFPI) on acute thrombu

68 Recombinant full-length tissue factor pathway inhibitor (RTFPI) was included in

69 Tissue factor pathway inhibitor significantly improves t

70 C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22alpha-TFPI) were su

71 ated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA t

72 r F5(L) (F5(L/L) ) and haploinsufficient for tissue factor pathway inhibitor (Tfpi(+/-) ).

73 ompared to HC, as were MPs expressing TF and Tissue Factor Pathway Inhibitor (TFPI) (all p < 0.0001).

74 It inhibits tissue factor pathway inhibitor (TFPI) activity and acce

75 d matrix metalloproteinases (MMPs) to cleave tissue factor pathway inhibitor (TFPI) and alter its act

76 interact with target plasma fXa inhibitors, tissue factor pathway inhibitor (TFPI) and antithrombin.

77 Low levels of mRNA for tissue factor pathway inhibitor (TFPI) and its variant,

78 Greater release of tissue factor pathway inhibitor (TFPI) and reduction in

79 activity, FVIII coagulant (FVIIIC) activity, tissue factor pathway inhibitor (TFPI) antigen, and thro

80 ependent inhibition of the enzyme complex by tissue factor pathway inhibitor (TFPI) are considered pr

81 thrombomodulin (TM), tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are markers of en

82 functions of the first two Kunitz domains of tissue factor pathway inhibitor (TFPI) are well defined

83 C, protein S, antithrombin III (AT-III), and tissue factor pathway inhibitor (TFPI) as well as combin

84 n of tissue factor-mediated coagulation with tissue factor pathway inhibitor (TFPI) attenuates neoint

85 Tissue factor pathway inhibitor (TFPI) blocks thrombin g

86 Tissue factor pathway inhibitor (TFPI) blocks tissue fac

87 (aPTT), plasma anti-Xa and anti-IIa levels, tissue factor pathway inhibitor (TFPI) concentration, an

88 in time (aPTT), anti-factors IIa and Xa, and tissue factor pathway inhibitor (TFPI) concentrations we

89 Tissue factor pathway inhibitor (TFPI) contains three Ku

90 Tissue factor pathway inhibitor (TFPI) down-regulates th

91 fibrin formation was associated with reduced tissue factor pathway inhibitor (TFPI) expression and in

92 Tissue factor pathway inhibitor (TFPI) forms a complex w

93 perties, the ability to cause the release of tissue factor pathway inhibitor (TFPI) from the endothel

94 Variation in the expression of tissue factor pathway inhibitor (TFPI) has also been pro

95 hird phase III study examining the effect of tissue factor pathway inhibitor (TFPI) in sepsis is curr

96 Tissue factor pathway inhibitor (TFPI) in vivo is though

97 Tissue factor pathway inhibitor (TFPI) inhibits tissue f

98 Tissue factor pathway inhibitor (TFPI) is a critical ant

99 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

100 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

101 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

102 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

103 Tissue factor pathway inhibitor (TFPI) is a major regula

104 Tissue factor pathway inhibitor (TFPI) is a multivalent

105 Tissue factor pathway inhibitor (TFPI) is a plasma serin

106 Tissue factor pathway inhibitor (TFPI) is a potent inhib

107 e now show that the endogenous anticoagulant tissue factor pathway inhibitor (TFPI) is also highly se

108 Tissue factor pathway inhibitor (TFPI) is an anticoagula

109 Tissue factor pathway inhibitor (TFPI) is an endogenous

110 Tissue factor pathway inhibitor (TFPI) is an endogenous

111 Tissue factor pathway inhibitor (TFPI) is an endogenous

112 Tissue Factor Pathway Inhibitor (TFPI) is the major inhi

113 Tissue factor pathway inhibitor (TFPI) is the major phys

114 Tissue factor pathway inhibitor (TFPI) is the major phys

115 Tissue factor pathway inhibitor (TFPI) is the primary ph

116 Tissue factor pathway inhibitor (TFPI) is the primary ph

117 Tissue factor pathway inhibitor (TFPI) localized at the

118 Tissue factor pathway inhibitor (TFPI) plays a key role

119 Tissue factor pathway inhibitor (TFPI) plays an importan

120 Tissue factor pathway inhibitor (TFPI) produces factor X

121 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI) that critically r

122 ) library, a clone with sequence homology to tissue factor pathway inhibitor (TFPI) was identified.

123 in vitro thrombin generation, and levels of tissue factor pathway inhibitor (TFPI) were strongly inc

124 shares significant homology with apo(a), on tissue factor pathway inhibitor (TFPI), a major regulato

125 a process which required cell surface-bound tissue factor pathway inhibitor (TFPI), a potent inhibit

126 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the

127 of the factor VIIa/tissue factor complex by tissue factor pathway inhibitor (TFPI), additional facto

128 ine whether treatment with recombinant human tissue factor pathway inhibitor (TFPI), an inhibitor of

129 sue factor complex inhibitors, DEGR VIIa and tissue factor pathway inhibitor (TFPI), and the selectiv

130 The effects of the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI), antithrombin-III

131 ein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI), effectively inhi

132 It displays high sequence similarity with a tissue factor pathway inhibitor (TFPI), Ixolaris, from t

133 The endothelium is a major source of tissue factor pathway inhibitor (TFPI), the endogenous r

134 Tissue factor pathway inhibitor (TFPI), the main inhibit

135 emains intact but is negatively regulated by tissue factor pathway inhibitor (TFPI), which inhibits b

136 Tissue factor pathway inhibitor (TFPI)-alpha, a key regu

137 nds our previous model by including: (a) the tissue factor pathway inhibitor (TFPI)-mediated inactiva

138 me, TF/FVIIa, can be reversibly inhibited by tissue factor pathway inhibitor (TFPI).

139 he presence and absence of plasma inhibitor, tissue factor pathway inhibitor (TFPI).

140 f TF-VIIa, Xa, and the Kunitz-type inhibitor tissue factor pathway inhibitor (TFPI).

141 on and LPS could be attenuated by hirudin or tissue factor pathway inhibitor (TFPI).

142 ated that APC sheds the Kunitz 1 domain from tissue factor pathway inhibitor (TFPI).

143 y due to decreased expression or function of tissue factor pathway inhibitor (TFPI).

144 ld interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI).

145 F.VIIa complex is the first Kunitz domain of tissue factor pathway inhibitor (TFPI-K1).

146 We identified tissue-factor pathway inhibitor (TFPI) as a biological i

147 o-hemostatic factors (tissue factor [TF] and tissue factor pathway inhibitor [TFPI-1]) are limited an

148 Tissue factor pathway inhibitor, the physiologic inhibit

149 r 9 shifted the balance of tissue factor and tissue factor pathway inhibitor toward procoagulant phen

150 Conversely, CpG DNA significantly reduced tissue factor pathway inhibitor transcription, secretion

151 n S, soluble endothelial protein C receptor, tissue factor pathway inhibitor, von Willebrand factor,

152 bitor from the mammalian anticoagulant TFPI (tissue factor pathway inhibitor), which is functionally

153 platelet factor V and, surprisingly, plasma tissue factor pathway inhibitor, which is significantly

154 mRNA level of TF but not of its counterpart-tissue factor pathway inhibitor, which was accompanied b